Cardiovascular

Paclitaxel-eluting coronary stent

The drug-coated stent platform that helped establish drug elution as a standard in cardiovascular medicine.

Development stage

Discovery
Preclinical
Clinical
Regulatory review
Marketed

Indication: Coronary artery restenosis
Commercial route: Licensed to interventional device manufacturers

About the programme

Combines an intravascular scaffold with a controlled-release paclitaxel coating so anti-proliferative therapy acts precisely at the treated vessel segment.

Coating chemistry governs elution kinetics over weeks, keeping local concentration in the therapeutic window without systemic exposure.

Our work here informed later generations of combination medical technologies well beyond the coronary artery.